← Back to Clinical Trials
Recruiting NCT07642193

NCT07642193 Rhomboid Intercostal Sub-serratus Plane Block Versus External Oblique Intercostal Block in Open Nephrectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07642193
Status Recruiting
Phase
Sponsor Cairo University
Condition Rhomboid Intercostal Sub-serratus Plane Block
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2026-05-02
Primary Completion 2026-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Rhomboid intercostal subserratus plane blockExternal oblique intercostal blockIntravenous morphine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2026-05-02 with a primary completion date of 2026-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare time of first request of analgesia among patients undergoing rhomboid intercostal sub-serratus plane block versus external oblique intercostal block for perioperative pain management in open nephrectomy.

Eligibility Criteria

Inclusion Criteria: * Both sexes. * American Society of Anesthesiologists (ASA) physical status II, III. * Body mass index (BMI): \> 20 kg/ m2 and \< 35 kg/ m2. * Patients undergoing open nephrectomy. Exclusion Criteria: * Patient refusal. * BMI \<20 kg/m2 and \>35 kg/m2 * Known sensitivity or contraindication to drug used in the study (local anesthetics, opioids). * History of psychiatric and cognitive disorders or chronic pain. * Contraindication to regional anesthesia e.g pre- existing peripheral neuropathies. * Severe respiratory or cardiac disorders. * Advanced liver or kidney disease. * Pregnancy. * Physical status ASA IV. * Coagulopathy with INR ≥ 1.6: hereditary (e.g. hemophilia, fibrinogen abnormalities \& deficiency of factor II) - acquired (e.g. impaired liver functions with prothrombin concentration less than 60 %, vitamin K deficiency \& therapeutic anticoagulants drugs).

Contact & Investigator

Central Contact

Amr R Seif, MD

✉ amroseifo40404@gmail.com

📞 00201066588692

Frequently Asked Questions

Who can join the NCT07642193 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Rhomboid Intercostal Sub-serratus Plane Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07642193 currently recruiting?

Yes, NCT07642193 is actively recruiting participants. Contact the research team at amroseifo40404@gmail.com for enrollment information.

Where is the NCT07642193 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07642193 clinical trial?

NCT07642193 is sponsored by Cairo University. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology